SignificanceAntiretroviral therapy cannot eradicate HIV-1 because the virus can become transcriptionally inactive in resting memory CD4+ T cells (and other cell types), which are long-lived, thus generating a reservoir undetectable by the immune system. When therapy is stopped, the latent viral reservoir is activated and HIV-1 rebounds. Our understanding of HIV-1 latency and reactivation is incomplete. Here we report that the heat shock protein 90 (Hsp90) regulates HIV-1 reactivation from latency by controlling the NF-kB pathway. Therefore Hsp90 is a key molecule linking HIV-1 reactivation from latency to CD4+ T-cell activation. Selective Hsp90 inhibitors combined with PKC-ϑ inhibitors, all in phase II clinical trials, potently suppressed HIV-1 reactivation, thus Hsp90 may be a novel target to control HIV-1 latency.